XORTX Therapeutics Inc. is a biopharmaceutical company with three clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221 for Type 2 Diabetic Nephropathy (T2DN). The Company has strong intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.
XORTX’s pipeline includes proprietary and novel product candidates currently in clinical development: XRx-101 to treat kidney and lung injury as well as health consequences associated with Coronavirus / COVID-19 infection, XRx-008 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for the treatment of Diabetic Nephropathy.
XORTX has received an important endorsement of its programs from the PKD Foundation (www.pkdcure.org) and is collaborating with the foundation. This collaboration will help advance XORTX’s programs to define the beneficial effects of XORTX’s therapies, in ADPKD patients but potentially in other forms of polycystic kidney disease as well. XORTX believes that there are substantial benefits to working with the leading polycystic kidney disease foundation in the world and that this collaboration on the development of treatments could redefine how physicians treat this disease in the future.
At XORTX, we are dedicated to advancing treatments that improve the care and quality of life of patients suffering from life-threatening diseases.